Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the aminopyrazine class. It features a pyrazinyl core substituted with chloro, difluoropyridinylethylamino, and fluoro-methylpyridinylylmethyl-acetamide groups. The drug is classified as experimental and has not been approved for any indication. Its mechanism of action is not explicitly described in public databases; however, related compounds in this structural class have been investigated as inhibitors of serine proteases such as thrombin. There are no known clinical trials or approved uses for this compound at present[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(6-chloro-3-{[2,2-difluoro-2-(2-pyridinyl)ethyl]amino}-2-oxo-1(2H)-pyrazinyl)-N-[(2-fluoro-3-methyl-6-pyridinyl)methyl]acetamide.